This is a pilot single-center prospective cohort. After inclusion, patients status (including magnesium levels) will be evaluated (1 and 3 months of treatment) and that status will define the exposure criterion. Included patients will be followed for 1 year during which cardiometabolic markers will be measured.
Patients will be recruited during consultations and stays in care units of Adult Psychiatry Unit of Montpellier University Hospital.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with severe mental illness (schizophrenia and other disorders chronic psychotic, schizoaffective disorder and bipolar disorder.
Patient naive to antipsychotic treatment or stopped for more than 3 months (more than 6 months for antipsychotic action extended) and requiring the introduction of antipsychotic therapy
Patient informed and accepting the proposed follow-up (himself or his/her legal representative)
Patient available for one year monitoring
Patient affiliated or beneficiary of a social security insurance
You may not be if
patient's opposition
Pregnant or breastfeeding patient
Patients on anti-psychotic or treatment stopped for less than 3 months (6 months for antipsychotic prolonged action)
Clareo Health | Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
